An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2
Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis
Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…Patient insights into the burden of OFF-episodes in Parkinson’s disease: Qualitative Interviews
Objective: Identify symptoms and impacts associated with OFF-episodes (OEs). Background: OFF-episodes are commonly experienced in patients with Parkinson’s disease (PD). Qualitative research into patients’ experience…Diplopia and visual complaints in non-demented patients with Parkinson disease: a Japanese single center cross-sectional survey
Objective: To investigate the characterization of diplopia and visual complaints including minor forms of hallucinations (mHals) in non-demented patients with Parkinson disease (PD). Background: Double…Analysis of Levodopa Content in Commercial Formulations of Mucuna pruriens Seeds Used in Integrative Treatment of Parkinson’s Disease
Objective: Objective: Formulations of Mucuna pruriens (MP) seed products are readily available through the internet and health food stores, and are used by some Parkinson's…Difference in perception of the wearing-off between patients and physicians in Parkinson’s disease
Objective: To explore if any inconsistency exists in the perception of the presence of wearing-off (WO) symptoms between patients and physicians in Parkinson’s disease (PD).…THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)
Objective: Impel NeuroPharma has developed the patient-friendly, self or caregiver actuatedPrecision Olfactory Delivery (IMPEL PODTM) device to achieve consistent upper nasal cavity drug delivery, rapid…Incremental hourly burden of “OFF” episodes on patient quality of life and health resource use among patients with Parkinson’s disease: A Neurologist/Patient Real World Assessment in the US
Objective: To investigate the incremental hourly burden of “OFF” episodes on health resource utilization (HRU) and health- related- quality of life (HRQoL) from a real…Chronological view of peak and diphasic dyskinesia, wearing off and freezing in Parkinson’s disease: 1212 Korean population
Objective: To evaluate the gross chronological trend of 4 motor complications - peak dose dyskinesia, diphasic dyskinesia, wearing off and freezing. Background: Dyskinesia, wearing off…A Real-world Assessment of Hospitalizations Due to Falls among Patients with and without OFF episodes in Parkinson’s Disease
Objective: To investigate the association between “OFF” episodes and hospitalizations due to falls among patients with Parkinson’s disease (PD) in a real-world setting. Background: Quantitative…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 24
- Next Page »